文献速递膀胱癌与上尿路尿路上皮癌前列腺增生与排尿功能障碍

同期经尿道膀胱肿瘤电切术与经尿道前列腺电切术的肿瘤学与安全性特征

Oncological and safety profiles in patients undergoing simultaneous transurethral resection (TUR) of bladder tumour and TUR of the prostate.
PubMed 文献 · BJU Int · 2022-10-03

该回顾性多中心研究纳入12家欧洲医院的762例男性患者,比较单纯经尿道膀胱肿瘤电切术(TURB)与同期TURB联合经尿道前列腺电切术(TURB+TURP)的肿瘤学结局与安全性。同期手术组复发率更低(28% vs 47%),无复发生存改善(HR 0.39),但进展无生存差异,且手术时间更长,并发症率相当。

要点

  • 同期TURB+TURP与单纯TURB相比,膀胱颈/前列腺窝复发更少(3% vs 55%)。
  • 同期手术与无复发生存改善相关(HR 0.39,95%CI 0.29-0.53),但进展无生存无差异(HR 1.63,95%CI 0.90-2.98)。
  • 同期手术不增加主要并发症(Clavien-Dindo ≥III级)率,但手术时间更长。

核心结论

  • 在当代队列中,同期TURB和TURP似乎是肿瘤学安全的选项,甚至可能通过预防膀胱颈和前列腺窝的疾病复发来改善无复发生存。

研究设计与样本

  • 回顾性分析12家欧洲医院接受单纯TURB或同期TURB+TURP治疗的患者,共762例男性,其中76%(581例)接受单纯TURB,24%(181例)接受TURB+TURP。
  • 采用倾向性评分匹配(PSM)1:1将TURB+TURP组与单纯TURB组患者匹配,PSM队列254例。
  • 在PSM前后使用Cox回归模型评估手术方式与无复发生存(RFS)和无进展生存(PFS)的关联。
  • 对具有复发风险因素(多灶性和/或肿瘤大小>3 cm)的患者进行亚组分析,亚组380例。

主要发现

  • 中位随访44个月,单纯TURB组复发率47%(更多),TURB+TURP组28%(P < 0.001)。
  • 单纯TURB组膀胱颈/前列腺窝复发55%,TURB+TURP组3%(P < 0.001)。
  • TURB+TURP与改善的RFS相关(HR 0.39,95%CI 0.29-0.53;P < 0.001),但与PFS无关(HR 1.63,95%CI 0.90-2.98;P = 0.11)。
  • 在PSM队列254例中,同期TURB+TURP仍与改善的RFS相关(HR 0.33,95%CI 0.22-0.49;P < 0.001)。
  • 在380例具有复发风险因素的患者亚组中,同期TURB+TURP与改善的RFS相关(HR 0.41,95%CI 0.28-0.62;P < 0.001)。

临床怎么用

  • 原文结论认为同期TURB和TURP似乎是肿瘤学安全的选项,甚至可能通过预防膀胱颈和前列腺窝的疾病复发来改善无复发生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the oncological impact and adverse events of performing simultaneous transurethral resection of bladder tumour (TURB) and transurethral resection of the prostate (TURP), as evidence on the outcomes of simultaneous TURB for bladder cancer and TURP for obstructive benign prostatic hyperplasia is limited and contradictory. PATIENTS AND METHODS: Patients from 12 European hospitals treated with either TURB alone or simultaneous TURB and TURP (TURB+TURP) were retrospectively analysed. A propensity score matching (PSM) 1:1 was performed with patients from the TURB+TURP group matched to TURB-alone patients. Associations between surgery approach with recurrence-free (RFS) and progression-free (PFS) survivals were assessed in Cox regression models before and after PSM. We performed a subgroup analysis in patients with risk factors for recurrence (multifocality and/or tumour size >3 cm). RESULTS: A total of 762 men were included, among whom, 76% (581) underwent a TURB alone and 24% (181) a TURB+TURP. There was no difference in terms of tumour characteristics between the groups. We observed comparable length of stay as well as complication rates including major complications (Clavien-Dindo Grade ≥III) for the TURB-alone vs TURB+TURP groups, while the latest led to longer operative time (P < 0.001). During a median follow-up of 44 months, there were more recurrences in the TURB-alone (47%) compared to the TURB+TURP group (28%; P < 0.001). Interestingly, there were more recurrences at the bladder neck/prostatic fossa in the TURB-alone group (55% vs 3%, P < 0.001). TURB+TURP procedures were associated with improved RFS (hazard ratio [HR] 0.39, 95% confidence interval [CI] 0.29-0.53; P < 0.001), but not PFS (HR 1.63, 95% CI 0.90-2.98; P = 0.11). Within the PSM cohort of 254 patients, the simultaneous TURB+TURP was still associated with improved RFS (HR 0.33, 95% CI 0.22-0.49; P < 0.001). This was also true in the subgroup of 380 patients with recurrence risk factors (HR 0.41, 95% CI 0.28-0.62; P < 0.001). CONCLUSION: In our contemporary cohort, simultaneous TURB and TURP seems to be an oncologically safe option that may, even, improve RFS by potentially preventing disease recurrence at the bladder neck and in the prostatic fossa.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Laukhtina E, Moschini M, Krajewski W, et al. Oncological and safety profiles in patients undergoing simultaneous transurethral resection (TUR) of bladder tumour and TUR of the prostate. BJU Int. 2022. PMID: 36134575. doi:10.1111/bju.15898

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。